论文部分内容阅读
目的 :探讨口腔鳞癌 4种新辅助化疗方案所产生的经济效果。方法 :收集我院 1995 .6.-2 0 0 3 .5 .间12 2例进行了 2个疗程新辅助化疗的住院口腔鳞癌患者 ,随机分为 4组 (Ⅰ～Ⅳ ) ,Ⅰ组 :卡铂 +平阳霉素 +氨甲碟呤 (CPM ) ;Ⅱ组 :平阳霉素 +氨甲碟呤 (PM ) ;Ⅲ组 :卡铂 +5 -氟脲嘧啶 (CF) ;Ⅳ组 :平阳霉素 (P) ,应用药物经济学的成本 -效果分析方法对 4种口腔鳞癌新辅助化疗方案进行评价。结果 :两个化疗疗程后 ,Ⅰ～Ⅳ组有效率分别为 61.3 6%、5 8.0 6%、65 .3 9%、42 .86% ;成本 -效果比分别为 49.2 9、78.63、2 9.11、10 2 .10。结论 :在 4种新辅助化疗方案中 ,CF方案疗效最好而成本 -效果比最低 ,因而CF方案为临床最合理方案
Objective: To investigate the economic effects of four neoadjuvant chemotherapy regimens for oral squamous cell carcinoma. Methods: A total of 122 hospitalized patients with oral squamous cell carcinoma who underwent two courses of neoadjuvant chemotherapy were enrolled in our hospital from 1995 to 2006. The patients were randomly divided into 4 groups (Ⅰ ~ Ⅳ), Ⅰ group Carboplatin + pingyangmycin + methotrexate (CPM); group Ⅱ: pingyangmycin + methotrexate (PM); group Ⅲ: carboplatin + 5 - fluorouracil (P), the use of cost-effectiveness of pharmaco-economics analysis of four kinds of oral squamous cell neoadjuvant chemotherapy program evaluation. Results: After two courses of chemotherapy, the effective rates of Ⅰ ~ Ⅳ were 61.36%, 58.0%, 65.39% and 42.86% respectively; the cost-effectiveness ratios were 49.2 9,78.63,2 9.11, 10 2 .10. CONCLUSIONS: Of the four neoadjuvant chemotherapeutic regimens, the CF regimen has the highest efficacy and the lowest cost-benefit ratio, so the CF regimen is the most clinically rational one